Syndax Pharmaceuticals just jumped 9.1% to US$14.29 after its third quarter 2026 report, a sharp move for a biotech that had fallen over the past month and quarter. Traders latched onto one thing first: revenue reached US$83.3m with Revuforj and Niktimvo now carrying the commercial story.
In the short term, that price pop reflects relief. The bigger story sits in the margin and balance sheet strain behind those sales, including ongoing losses and flagged negative equity. For anyone looking beyond today’s chart, the key question is how long this cash and growth profile can support the current valuation.
Love the revenue momentum at Syndax Pharmaceuticals but concerned about the ongoing losses and balance sheet pressure? Screen for biotechs with stronger cash positions and healthier fundamentals in our list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs. Q3 2025): US$83.3m vs. US$45.9m (strong year-over-year increase in revenue)
- Net Loss (Q3 2026 vs. Q3 2025): US$49.4m loss vs. US$60.7m loss (loss narrowed compared to the prior year quarter)
- Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.55 per share vs. loss of US$0.70 per share (per share loss improved compared to Q3 last year)
- TTM Revenue (Q3 2026 vs. Q3 2025): US$289.7m vs. US$111.3m (significant increase in trailing twelve-month revenue for Syndax Pharmaceuticals)
Tired of wading through dense earnings releases and raw figures for Syndax Pharmaceuticals? Get a clear visual overview of the company, including its balance sheet strength and funding runway, in the interactive company report for Syndax Pharmaceuticals.
Syndax Bull Case: Menin Uptake Goals On Trial
Supporters argue that Syndax Pharmaceuticals can turn early traction into a much bigger business if Revuforj use broadens across leukemia settings and is kept on longer.
"The main requirement for this thesis is continued expansion of Revuforj use across relapsed or refractory and frontline acute leukemia segments, including longer treatment duration and higher post transplant restart rates."
Q3 points in that direction. Revuforj delivered the majority of Syndax Pharmaceuticals revenue, with management citing the seventh straight quarter of double digit sequential growth, more new patients and rising post transplant maintenance in both KMT2A and NPM1 groups. All of these factors align with that usage focused target.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.
Syndax Bears Focus On Concentration And Spend
Bearish views argue that Syndax Pharmaceuticals could stay too tied to a narrow product set while expenses run hot.
"Although the company is building a broader oncology and fibrosis pipeline that includes next generation menin inhibition and an allosteric EGFR inhibitor, the recent price target cuts that incorporate updated AML market assumptions highlight that heavy R&D and SG&A spending near US$400 million in 2026 may not translate into the revenue scale needed to offset ongoing net losses. This could pressure earnings if newer assets do not ramp quickly."
Q3 results do not remove that worry. Revenue beat expectations, yet the loss of US$49.4m was slightly worse than forecast and spending guidance around US$400m is unchanged, so operating leverage is still deferred rather than visible.
Hunt Quiet Disconnects In Plain View
Syndax Pharmaceuticals recently highlighted how quickly sentiment can change around a single earnings report. The real opportunity is finding stocks where expectations and current pricing may not align.
- Company 1 - 36% below our estimate - scales branded and private label coconut beverages as retailers increase shelf space for the category.
- Company 2 - 25% below our estimate - adds higher value photonics programs to utilize expanded manufacturing capacity serving AI-focused data centers.
- Company 3 - 23% below our estimate - rides a growing backlog of hyperscale data center projects through electrical and infrastructure work.
Three companies from the same screener. Open the full list of 34 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com